Abstracts tagged "B cells"

Abstract Number: 1089 • 2016 ACR/ARHP Annual Meeting
Decreased B Cell Activation-Induced Apoptosis in Cells Overexpressing Interferon Regulatory Factor 5 (IRF5), a Gene Associated with Risk for Systemic Lupus Erythematosus and Other Autoimmune Diseases
Brian Poole¹, Caleb Cornaby², Kalare Eberting², Wesley Cheney², Grant Walker², Craig Smith², Tosh Dowling² and Emily Mello², ¹Brigham Young University, Provo, UT, ²Microbiology and Molecular Biology, Brigham Young University, Provo, UT
Background/Purpose: The transcription factor Interferon Regulatory Factor 5 (IRF5) plays a crucial role in the functioning of several cell types such as macrophages, dendritic, and…
Abstract Number: 2110 • 2016 ACR/ARHP Annual Meeting
Synovial Fibroblasts Regulate B Cell Survival Via B Cell Activating Factor of the TNF Family (BAFF)
Torsten Lowin¹, Matthias Schneider² and Georg Pongratz³, ¹Rheumatology, University Hospital Duesseldorf, Duesseldorf, Germany, ²Rheumatology - Hiller Research Center Rheumatology, University Hospital Duesseldorf, Düsseldorf, Germany, ³Rheumatology - Hiller Research Center Rheumatology, University Hospital Duesseldorf, Duesseldorf, Germany
Background/Purpose: In rheumatoid arthritis (RA), synovial fibroblasts (SF) are one main contributor of joint destruction since they resist apoptosis and secrete pro-inflammatory cytokines and matrix…
Abstract Number: 3163 • 2016 ACR/ARHP Annual Meeting
SEC16A and Intracellular Trafficking Abnormalities in Axial Spondyloarthritis
Fanxing Zeng¹, Zhenbo Zhang¹, Vidya Ranganathan², Darren Orielly³, Proton Rahman⁴ and Nigil Haroon⁵, ¹Krembil research institute, Toronto, ON, Canada, ²University Health Network, Toronto, ON, Canada, ³Faculty of Medicine, Memorial University of Newfoundland, St. John’s, NF, Canada, ⁴Rheumatology, St Claires Mercy Hospital, St Johns, NF, Canada, ⁵Rheumatology, Toronto Western Hospital, University of Toronto, Spondylitis Clinic, Toronto, ON, Canada
Background/Purpose: The pathogenesis of Axial Spondyloarthritis (AxSpA) is not well understood. A rare 9 base-pair deletion of SEC16A was recently identified to be strongly associated with AxSpA in a multiplex…
Abstract Number: 4L • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Epratuzumab in Patients with Moderate-to-Severe Systemic Lupus Erythematosus: Results from Two Phase 3 Randomized, Placebo-Controlled Trials
Megan E. B. Clowse¹, Daniel J Wallace², Richard Furie³, Michelle Petri⁴, Marilyn Pike⁵, Piotr Leszczynski⁶, C Michael Neuwelt⁷, Kathryn Hobbs⁸, Mauro Keiserman⁹, Liliana Duca¹⁰, Kenneth Kalunian¹¹, Sabine Bongardt¹², Christian Stach¹², Carolyn Beaudot¹³, Brian Kilgallen¹³, Catrinel Galateanu¹⁴ and Caroline Gordon^15,16, ¹Rheumatology, Duke University, Durham, NC, ²Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ³North Shore LIJ Health System, Manhasset, NY, ⁴Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Med Pharm Consulting Inc, Cambridge, MA, ⁶Dept. of Rheumatology and Clinical Immunology, J. Strus Poznan Municipal Hospital, Poznan University of Medical Sciences, Poznan, Poland, ⁷Division of Rheumatology, Alameda County Medical Center, Oakland, CA, ⁸Denver Arthritis Clinic, Denver, CO, ⁹School of Medicine, Pontifical Catholic University, Porto Alegre, Brazil, ¹⁰Clinica Neomed, Brasov, Romania, ¹¹UCSD School of Medicine, La Jolla, CA, ¹²UCB Pharma, Monheim, Germany, ¹³UCB Pharma, Raleigh, NC, ¹⁴UCB Pharma, Brussels, Belgium, ¹⁵Rheumatology Research Group, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ¹⁶NIHR/Wellcome Trust Clinical Research Facility, University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom
Background/Purpose: In phase 2b trials, epratuzumab, a humanized anti-CD22 mAb that modulates B cell signaling without total B cell depletion, significantly improved disease activity in…
Abstract Number: 738 • 2015 ACR/ARHP Annual Meeting
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the BCL-2 Inhibitor Venetoclax (ABT-199) in a Phase 1 Single and Multiple Ascending Dose Study in Female Patients with Systemic Lupus Erythematosus
Peng Lu¹, Roy Fleischmann², Craig Curtis³, Stanislav Ignatenko⁴, Monali Desai⁵, Shekman L. Wong⁵, Kristie M. Grebe¹, Jiewei Zeng⁵, Jeroen Medema⁵ and James Stolzenbach⁵, ¹AbbVie Inc., Worcester, MA, ²University of Texas Southwestern Medical Center, Dallas, TX, ³Compass Research Center, Orlando, FL, ⁴Charité Research Organization, Berlin, Germany, ⁵AbbVie Inc., North Chicago, IL
Background/Purpose: Apoptosis is needed to eliminate auto-reactive T and B cells during immune responses; failure of elimination is important in development of systemic lupus erythematosus…
Abstract Number: 1115 • 2015 ACR/ARHP Annual Meeting
B Cell-Intrinsic Interferon Gamma Signals Promote the Development of Systemic Lupus Erythematosus By Enhancing the Formation of Spontaneous Autoimmune Germinal Centers
Shaun Jackson, Nicole Scharping, Holly Jacobs, Tanvi Arkatkar, Socheath Khim and David Rawlings, Seattle Children's Research Institute, Seattle, WA
Background/Purpose: Type 1 interferon (IFN) is strongly implicated in lupus pathogenesis, and SLE patients frequently express a “type 1 IFN gene signature”. The type 2…
Abstract Number: 1934 • 2015 ACR/ARHP Annual Meeting
Autophagy Pathway As a Target of Therapeutic P140 Peptide Used in Lupus
Maud Wilhelm¹, Fengjuan Wang², Nicolas Schall², Michael Faludi³, Jean Francois Kleinmann⁴, Emil P. Nashi⁵, Thierry Martin⁶, Jean Sibilia⁷, Jean-Louis Pasquali⁸, Daniel Wallace⁹ and Sylviane Muller¹⁰, ¹Immunopathologie & Chimie Thérapeutique, CNRS, Strasbourg, France, ²CNRS, Strasbourg, France, ³761 Graham, McGill University, Mont-Royal, QC, Canada, ⁴Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁵Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁶Cnrs UPR9021, IBMC, Strasbourg, France, ⁷Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁸Strasbourg University, Hospital, CNRS UPR 3572, Strasbourg, France, ⁹Cedars-Sinai/UCLA, Los Angeles, CA, ¹⁰CNRS Institut de Biologie Moléculaire et Cellulaire, Strasbourg, France
Background/Purpose: P140 is a 21-mer peptide (sequence 131-151, phosphorylated at position 140) that is derived from the spliceosomal protein U1-70K. In a multicenter, randomized, placebo-controlled…
Abstract Number: 1052 • 2015 ACR/ARHP Annual Meeting
Identification of Novel Sjogren’s Syndrome Risk Loci in the Regions of TNFAIP3 and PRDM1
Christopher J. Lessard^1,2, He Li^1,2, John Ice², Indra Adrianto³, Astrid Rasmussen², Kiely Grundahl⁴, Jennifer A. Kelly⁵, Corinne Miceli⁶, Simon Bowman⁷, Susan Lester⁸, Johan G. Brun^9,10, Lasse G. Goransson¹¹, Erna Harboe¹¹, Joel M. Guthridge², Kenneth M. Kaufman^12,13, Per Eriksson¹⁴, Maija-Leena Eloranta¹⁵, Marika Kvarnström¹⁶, Deborah S. Cunninghame-Graham¹⁷, A. Darise Farris², Michael T. Brennan¹⁸, James Chodosh¹⁹, Raj Gopalakrishnan²⁰, Andrew J.W. Huang²¹, Pamela Hughes²², David M. Lewis²³, Lida Radfar²⁴, Michael D. Rohrer²⁵, Donald U. Stone²⁶, Timothy J. Vyse¹⁷, Patrick M. Gaffney², Judith A. James^1,5,27, John B. Harley^12,28, Roald Omdal¹¹, Marie Wahren-Herlenius¹⁶, Gabor G. Illei²⁹, Torsten Witte³⁰, Roland Jonsson^10,31, Maureen Rischmueller^32,33, Lars Rönnblom³⁴, Xavier Mariette³⁵, Juan-Manuel Anaya³⁶, Wan-Fai Ng³⁷, Gunnel Nordmark³⁴, Courtney G. Montgomery², Nelson L. Rhodus³⁸, Barbara M. Segal³⁹, R. Hal Scofield^2,27,40 and Kathy L. Sivils^1,2, ¹Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma CIty, OK, ⁵Arthritis & Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Rheumatology, PARIS, France, ⁷Rheumatology Dept, University Hospital Birmingham, Birmingham, United Kingdom, ⁸Queen Elizabeth Hospital, Adelaide, Australia, ⁹Institute of Internal Medicine, University of Bergen, Bergen, Norway, ¹⁰Department of Rheumatology, Haukeland University Hospital, Bergen, Norway, ¹¹Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, ¹²US Department of Veterans Affairs Medical Center, Cincinnati, OH, ¹³Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁴Department of Clinical and Experimental Medicine, Rheumatology/AIR, Linköping University, Linköping, Sweden, Linköping, Sweden, ¹⁵Department of Medical Sciences, SciLife Lab, Rheumatology, Uppsala University, Uppsala, Sweden, Uppsala, Sweden, ¹⁶Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ¹⁷Department of Medical and Molecular Genetics, King's College London, London, United Kingdom, ¹⁸Department of Oral Medicine, Carolinas Medical Center, Charlotte, NC, ¹⁹Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, ²⁰Diagnostic and Biological Sciences, Division of Oral Pathology, University of Minnesota, Minneapolis, MN, ²¹Department of Ophthalmology and Visual Sciences, Washington University, St Louis, MO, ²²Division of Oral and Maxillofacial Surgery, Department of Developmental and Surgical Science, University of Minnesota School of Dentistry, Minneapolis, MN, ²³College of Dentistry, Department of Oral and Maxillofacial Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²⁴Oral Diagnosis and Radiology Department, University of Oklahoma Health Sciences Center College of Dentistry, Oklahoma City, OK, ²⁵Hard Tissue Research Laboratory, University of Minnesota School of Dentistry, Minneapolis, MN, ²⁶Department of Ophthalmology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²⁷Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²⁸Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²⁹National Institute of Dental and Craniofacial Research, NIH, Bethesda, MD, ³⁰Hannover Medical School, Hanover, Germany, ³¹Broegelmann Research Laboratory, The Gade Institute, University of Bergen, Bergen, Norway, ³²University of Adelaide, Adelaide, Australia, ³³Department of Rheumatology, The Queen Elizabeth Hospital, Adelaide, Australia, ³⁴Rheumatology, Department of Medical Sciences and Science for Life Laboratory, Uppsala University, Uppsala, Sweden, ³⁵AP-HP, Hopitaux Universitaires Paris-Sud, Université Paris-Sud, Paris, France, ³⁶Center for Autoimmune Diseases Research (CREA), Universidad del Rosario, Bogotá, Colombia, ³⁷Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, ³⁸Department of Oral Surgery, University of Minnesota School of Dentistry, Minneapolis, MN, ³⁹Division of Rheumatology, University of Minnesota Medical School, Minneapolis, MN, ⁴⁰US Department of Veterans Affairs Medical Center, Oklahoma City, OK
Background/Purpose: Sjögren’s syndrome (SS) is a complex autoimmune disease with both environmental and genetic factors playing important roles in its pathophysiology. The goal of this…
Abstract Number: 1116 • 2015 ACR/ARHP Annual Meeting
Decreased Expression of Negative Regulators of Toll-like Receptor Signaling and Increased TLR7 Responsiveness in Expanded IgD- CD27- B Cells from Systemic Lupus Erythematosus Patients
Scott Jenks¹, Benjamin Barwick² and Ignacio Sanz³, ¹Allergy, Immunology, and Rheumatology, Emory University School of Medicine, Atlanta, GA, ²Emory University, Altanta, GA, ³Medicine, Emory University, Atlanta, GA
Background/Purpose: B cell homeostasis is perturbed in SLE patients; in particular many patients with active disease have a large expansion of IgD- CD27- B cells…
Abstract Number: 1942 • 2015 ACR/ARHP Annual Meeting
B Cell Depletion By Rituximab in Lymphocyte Subpopulations from Peripheral Blood in Patients with Rheumatoid Arthritis
Leticia Merino-Meléndez¹, Jorge López-López², Irene Llorente¹, Santos Castañeda³, Federico Herrera², Teresa Velasco⁴, Lorena Vega⁵, Francisco Rodriguez⁵, Jose María Alvaro-Gracia³, Rosario Garcia-Vicuña⁶, Cecilia Muñoz-Calleja² and Isidoro Gonzalez-Alvaro⁷, ¹Rheumatology, H.U. La Princesa, Madrid, Spain, ²Immunology, Hospital Universitario de La Princesa, Madrid, Spain, ³Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ⁴Rheumatology, H.U La Princesa, Madrid, Spain, ⁵H.U. La Princesa, Madrid, Spain, ⁶Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ⁷Hospital Univ. de La Princesa, IIS Princesa, Madrid, Spain
Background/Purpose: Rheumatoid arthritis (RA) is a chronic disease that leads to inflammation of the joints and other tissues. Rituximab (Rtx) is a therapeutic monoclonal antibody…
Abstract Number: 1073 • 2015 ACR/ARHP Annual Meeting
B Cell Subsets Are Epigenetically and Transcriptionally Dysregulated in Systemic Lupus Erythematosus
Emily Blalock¹, Chris Scharer², Ben Barwick², Scott Jenks³, Bridget Neary³, Jeremy Boss² and Ignacio Sanz^3,4, ¹Emory University School of Medicine, Atlanta, GA, ²Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA, ³Rheumatology, Emory University School of Medicine, Atlanta, GA, ⁴Medicine, Emory University, Atlanta, GA
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by multiple B cell abnormalities, including the production of autoantibodies, a major contributing factor to disease pathogenesis. Epigenetic…
Abstract Number: 1118 • 2015 ACR/ARHP Annual Meeting
Role of the Chemokine Receptor CXCR3 in the Function of Regulatory B Cells in Patients with SLE
Shun-ichiro Ota^1,2, Hiroaki Niiro³, Naoko Ueki^2,4, Yuri Hirosaki², Hirofumi Tsuzuki², Siamak Jabbarzadeh-Tabrizi², Tsuyoshi Nakayama², Koji Mishima², Ayako Takaki², Hiroki Mitoma², Mitsuteru Akahoshi², Yojiro Arinobu², Hiroshi Tsukamoto² and Koichi Akashi², ¹Department of Rheumatology, Internal medicine and connective tissue disorders, Shimonoseki City Hospital, Shimonoseki, Japan, ²Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan, ³Clinical Education Center, Kyushu University Hospital, Fukuoka, Japan, ⁴Division of Nephrology and Rheumatology, Fukuoka University, Fukuoka, Japan
Background/Purpose: The emerging application of B-cell directed therapies in autoimmune diseases has led to the discovery of a novel B cell population, referred to as…
Abstract Number: 2460 • 2015 ACR/ARHP Annual Meeting
B10 Cells May be Involved in Controlling Disease Activity in Polyarticular Juvenile Idiopathic Arthritis Patients
Qianzi Zhao¹ and Lawrence K. Jung², ¹Rheumatology, Children's National Medical Center, Washington, DC, ²Pediatric Rheumatology, Children's National Medical Center, Washington, DC
Background/Purpose: In addition to antibodies production, B cells have been shown to have down-regulatory function on immune response in both mouse and human. The down-regulatory…
Abstract Number: 1096 • 2015 ACR/ARHP Annual Meeting
B Cells Are Prime Producers of Tumor Necrosis Factor Alpha in Rheumatoid Arthritis
Victor Wang¹, Nida Meednu¹, Wen Sun², Javier Rangel-Moreno³, Lianping Xing² and Jennifer H. Anolik¹, ¹Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ²Pathology & Lab Medicine, University of Rochester Medical Center, Rochester, NY, ³Medicine- Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease, which causes joint inflammation and bone loss. Inflammation-mediated joint damage is linked to the imbalance of…
Abstract Number: 1120 • 2015 ACR/ARHP Annual Meeting
Analysis of SLE Plasmablasts By High Throughput Pairing of the Immunoglobulin Heavy and Light Chain (VH-VL)
Deepak Tomar¹, Christopher Tipton¹ and Ignacio Sanz², ¹Medicine/Rheumatology, Emory University School of Medicine, Atlanta, GA, ²Rheumatology, Emory University School of Medicine, Atlanta, GA
Background/Purpose: In-depth analysis of the molecular and antigenic properties of antibody secreting cells (ASC) is critical for our understanding of autoimmune diseases. This goal however…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.